The IDO1 Knockout HGC-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human gastric adenocarcinoma cell line HGC-27, designed for functional disruption of the IDO1 gene. This loss-of-function model avoids clonal selection biases, preserving natural phenotypic variation for studies of indoleamine 2,3-dioxygenase 1 in a gastric epithelial context. The polyclonal knockout strategy enables robust interrogation of IDO1-dependent mechanisms in tryptophan metabolism and immune modulation without the constraints of monoclonal editing patterns.
HGC-27 is a poorly differentiated gastric adenocarcinoma epithelial cell line that serves as a relevant model for gastric cancer biology. These cells exhibit characteristic features of malignancy, including anchorage-independent growth and invasive capacity, and are commonly employed in xenograft studies, drug screening, and tumor microenvironment research. The genetic and phenotypic properties of HGC-27 provide an appropriate platform for evaluating the impact of IDO1 ablation on gastric tumor cell behavior and interactions with immune components.
IDO1 is a heme-containing enzyme that catalyzes the rate-limiting step of tryptophan catabolism, producing kynurenine. Its expression is strongly upregulated by interferon-gamma (IFN-??), tumor necrosis factor-alpha (TNF-??), Toll-like receptor (TLR) agonists, and interleukin-1 beta (IL-1??). The resulting tryptophan depletion and kynurenine accumulation activate the aryl hydrocarbon receptor (AhR) and the stress kinase GCN2, while also influencing mTORC1 signaling. These events lead to suppression of effector T cells and promotion of immunosuppressive cell populations, facilitating tumor immune evasion.
In HGC-27 cells, IDO1-driven tryptophan metabolism is anticipated to contribute to the immunosuppressive microenvironment of gastric adenocarcinoma. Disruption of IDO1 allows dissection of how kynurenine pathway signaling, AhR transcriptional activity, and downstream immune modulators are altered in a gastric cancer background. By comparing knockout and wild-type cells, researchers can pinpoint IDO1-specific roles in immune checkpoint resistance, apoptosis regulation, and tumor-stroma crosstalk.
This polyclonal knockout model is suited for cancer immunotherapy and tumor immunology studies, including co-culture experiments with immune cells to assess T-cell proliferation, cytokine profiling, and apoptosis. Key assays such as IDO1 activity measurements, Western blot, RT-qPCR, and flow cytometry enable monitoring of pathway components like AhR and GCN2. The product supports investigation of IDO1-dependent immune evasion mechanisms and validation of therapeutic targets. For technical inquiries, please contact Ascent Research.
